Tamminga C A, Mack R J, Granneman G R, Silber C J, Kashkin K B
Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore 21228, USA.
Int Clin Psychopharmacol. 1997 Feb;12 Suppl 1:S29-35. doi: 10.1097/00004850-199702001-00005.
Evidence from clinical trials supports the claim that sertindole is a potent antipsychotic drug at a dose of 12-24 mg/day. Its action against positive symptoms is as potent as that of the traditional antipsychotic haloperidol. Its action against negative symptoms is significantly different from that of placebo and quantitatively larger than that of haloperidol. Its most distinctive characteristic is a reduction in motor side effects over a whole range of comparable drug and comparator doses. More work is needed to determine whether sertindole's actions against negative symptoms influence the primary or the secondary negative system. There are insufficient data at present to compare sertindole with the highly efficacious drug clozapine or the other new antipsychotic olanzapine.
在每日12 - 24毫克的剂量下，塞汀多是一种强效抗精神病药物。它对抗阳性症状的作用与传统抗精神病药物氟哌啶醇相当。它对抗阴性症状的作用与安慰剂有显著差异，且在数量上大于氟哌啶醇。其最显著的特点是在一系列可比药物和对照剂量范围内，运动副作用减少。需要更多研究来确定塞汀多对抗阴性症状的作用是影响原发性还是继发性阴性系统。目前尚无足够数据将塞汀多与高效药物氯氮平或其他新型抗精神病药物奥氮平进行比较。
